生物异构剂类型的MDMA:改善药理学概况?
Ana Sofia Alberto-Silva1, Selina Hemmer2, Hailey A Bock3
1Center for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, Vienna, Austria.
Journal of neurochemistry
|June 20, 2024
概括
三种新的3,4-Methylenedioxymethamphetamine (MDMA) 的甲基二氧化生物异构体显示出类似的输送活性,但受体结合减少和代谢发生改变. 这些化合物可能为神经精神疾病提供比MDMA更安全的治疗替代品.
科学领域:
- 药理学和药物化学 药理学和药物化学
- 神经科学是一个神经科学.
- 药物代谢和药理动力学
背景情况:
- 3,4-甲基二氧化甲胺 (MDMA) 显示神经精神疾病的治疗潜力,但有不良影响.
- 研究MDMA生物异构体对于开发更安全的治疗替代方案至关重要.
研究的目的:
- 评估MDMA的三个新型甲基二氧化物生物异构体,以评估它们的非目标药理学特征.
- 为了比较它们的转运器相互作用,受体活性和肝脏代谢与MDMA.
主要方法:
- 在体外测定包括放射性追踪剂结合,电生理学和代谢稳定性研究.
- 在的分子对接.
- 对与人体血清激素 (hSERT),多巴胺 (hDAT),上腺素 (hNET),5-HT2A/2C受体,有机阴离子载体 (hOCT) 和血单胺载体 (hPMAT) 的相互作用进行分析.
主要成果:
- 与MDMA相比,MDMA生物同位素 (ODMA,TDMA,SeDMA) 在hSERT,hDAT和hNET表现出类似的活性.
- 在生物异构体的5-HT2A/2B/2C受体上观察到降低的激素活性.
- 生物异构体表现出明显的肝脏代谢概况,缺乏II期代谢物,与hOCT1,hOCT2和hPMAT的相互作用较弱.
结论:
- 研究的MDMA生物异构体保留了关键的输送活性,同时减少了非目标受体相互作用.
- 替代性肝脏代谢和与hOCT和hPMAT的较弱相互作用表明,安全性可能有所改善.
- 这些化合物代表了MDMA有希望的治疗替代品,需要进一步调查.
相关概念视频
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.9K
01:22CNS Stimulants: Psychedelic Agents
146
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
146
01:25Adrenergic Agonists: Indirect-Acting Agents
1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K
01:28Structure-Activity Relationships and Drug Design
699
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
699
01:28Adrenergic Agonists: Mixed-Action Agents
701
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
701
01:16Bioequivalence: Overview
991
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
991